Professor
Max Rady College of Medicine
Internal Medicine
2LB19 – 2300 McPhillips Street
Winnipeg, Manitoba, R2V3M3
204-631-3834
Fax: 204-632-3660
claudio.rigatto@umanitoba.ca
The University of Manitoba campuses are located on original lands of Anishinaabeg, Ininew, Anisininew, Dakota and Dene peoples, and on the National Homeland of the Red River Métis. More
University of Manitoba
Winnipeg, Manitoba Canada, R3T 2N2
Max Rady College of Medicine
Internal Medicine
2LB19 – 2300 McPhillips Street
Winnipeg, Manitoba, R2V3M3
204-631-3834
Fax: 204-632-3660
claudio.rigatto@umanitoba.ca
Department of Community Health Sciences
Dr. Rigatto’s research is conducted in close collaboration with Dr. Navdeep Tangri and Dr. Paul Komenda as part of the Seven Oaks General Hospital Research Centre.
Dr. Rigatto and his team have conducted groundbreaking research on biomarkers of cardiac surgery-associated acute kidney injury (CSA-AKI) and cardiac disease in patients with kidney disease. Their work has resulted in the identification and characterization of hepcidin-25 as a novel biomarker associated with protection from AKI and the establishment of the prognostic importance of small changes in creatinine in the prediction of AKI after heart surgery. Additionally, they were the first to demonstrate that congestive heart failure (CHF) is as frequent as ischemic heart disease in kidney transplant patients and that CHF confers an adverse risk of death that is similar to, and independent of, IHD.
Their research on CKD has challenged the prevailing hypothesis that CKD is a state of accelerated atherosclerosis, demonstrating that carotid plaque area grows slower, not faster, in patients with the lowest creatinine clearance. Dr. Rigatto's research themes include telemonitoring in high-risk CKD, biomarkers of cardiovascular disease in CKD, biomarkers of AKI, and the development and validation of risk prediction models in kidney disease.
Overall, Dr. Rigatto's extensive research background has contributed significantly to the advancement of medical knowledge in the areas of AKI, CKD, and cardiovascular disease, making him a highly regarded expert in the field of nephrology. His work has implications for the epidemiology of CKD and the management of kidney transplant patients.
Academic director, Chronic Disease Innovation Centre Institution
Dr. Claudio Rigatto is an attending physician and professor in the division of nephrology at the University of Manitoba, where he also holds a position in the department of community health sciences. Dr. Rigatto was head of the section of nephrology from 2013-2019, leading a team of 26 academic kidney specialists. He is a founding member and academic director of the Chronic Disease Innovation Centre at the Seven Oaks Hospital.
Dr. Rigatto completed his MD at the University of Manitoba and his master's degree in clinical epidemiology at Memorial University of Newfoundland. He also holds a bachelor of science in medicine from the University of Manitoba and a bachelor of arts (honours) in physics/Italian from Queen's University in Kingston, Ontario.
Dr. Rigatto has received numerous awards and scholarships throughout his career, including the Richard Hoeschen Memorial Award and the Biomedical Research Fellowship Award from the Kidney Foundation of Canada.
Master of Science (M.Sc.), clinical epidemiology, Memorial University of Newfoundland, Canada (1998 – 2001)
Bachelor of science (B.Sc.), Medicine, University of Manitoba, Canada (1993 – 1997)
Doctor of medicine (MD), University of Manitoba, Canada (1989 – 1993)
Bachelor of arts (BA) (honours), physics/Italian, Queen’s University, Canada (1985 – 1988)
Internal Medicine
Room GC430, Health Sciences Centre
820 Sherbrook Street
University of Manitoba
Winnipeg, MB R3A 1R9 Canada